NeuroCores

Executive Summary

NeuroCores Inc. is a pre-clinical biotechnology company headquartered in Cambridge, MA, dedicated to developing novel oral small molecule plasmalogen derivatives for the treatment of rare pediatric neurological disorders and neurodegenerative diseases. Leveraging foundational research from a prestigious Japanese institution, the company targets plasmalogen deficiency—a root cause of neuroinflammation and cellular dysfunction. Its lead asset is focused on Rett syndrome, a severe neurodevelopmental disorder with no approved disease-modifying therapies, and has received significant FDA designations (Orphan Drug, Rare Pediatric Disease, Fast Track). NeuroCores is currently advancing its pipeline toward IND-enabling studies, positioning itself to address high-unmet medical needs in diseases driven by plasmalogen loss.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead asset in Rett syndrome60% success
• Q3 2026Series B financing round completion70% success
• H2 2026Preclinical proof-of-concept data in additional indications75% success